Parikh Kishan S, Ahmad Tariq, Fiuzat Mona
Division of Cardiology, Duke University Medical Center, 3428, Durham, NC 27710, USA.
Division of Cardiology, Duke University Medical Center, 3428, Durham, NC 27710, USA; Duke Clinical Research Institute, DUMC Box 3356, Durham, NC 27710, USA.
Heart Fail Clin. 2014 Oct;10(4):599-606. doi: 10.1016/j.hfc.2014.07.007. Epub 2014 Aug 15.
Pharmacogenomics explores one drug's varying effects on different patient genotypes. A better understanding of genomic variation's contribution to drug response can impact 4 arenas in heart failure (HF): (1) identification of patients most likely to receive benefit from therapy, (2) risk stratify patients for risk of adverse events, (3) optimize dosing of drugs, and (4) steer future clinical trial design and drug development. In this review, the authors explore the potential applications of pharmacogenomics in patients with HF in the context of these categories.
药物基因组学研究一种药物对不同患者基因型的不同影响。更好地理解基因组变异对药物反应的作用可在心力衰竭(HF)的四个领域产生影响:(1)识别最有可能从治疗中获益的患者;(2)对患者发生不良事件的风险进行分层;(3)优化药物剂量;(4)指导未来的临床试验设计和药物开发。在本综述中,作者在这些类别范围内探讨了药物基因组学在HF患者中的潜在应用。